News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Catabasis Pharmaceuticals, Inc. Demonstrates CAT-2003 Lowers Fed And Fasting Triglycerides In Studies Presented At Lipid Conferences


5/5/2014 6:41:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Catabasis Pharmaceuticals Inc. today announced the presentation of clinical and preclinical data demonstrating that CAT-2003 lowers fasting triglycerides in addition to postprandial (fed) triglycerides. The Phase 1 clinical data were presented by Catabasis Chief Medical Officer Joanne Donovan, M.D., Ph.D., at the National Lipid Association (NLA) Scientific Sessions 2014, and the preclinical data were presented by Feng Liu, Ph.D., at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES